Indomethacin

證據等級: L5

預測適應症: 10 個

Indomethacin: From Inflammatory Arthritis to Juvenile Idiopathic Arthritis

One-Sentence Summary

Indomethacin is a potent non-steroidal anti-inflammatory drug (NSAID) with decades of clinical history, originally used to treat inflammatory conditions including rheumatoid arthritis, ankylosing spondylitis, and gouty arthritis. The TxGNN model predicts it may be effective for Juvenile Idiopathic Arthritis (JIA) — the most evidenced actionable candidate among 10 predicted indications — supported by 0 registered clinical trials and 20 publications. Among all predicted indications, JIA (Rank 8) carries the strongest mechanistic grounding and achieves the highest evidence level (L2) with a "Proceed with Guardrails" recommendation.

Quick Overview

Item	Content
Original Indication	Inflammatory arthritis and pain conditions (rheumatoid arthritis, ankylosing spondylitis, gout) — no Singapore registration on record
Predicted New Indication	Juvenile Idiopathic Arthritis (JIA)
TxGNN Prediction Score	99.84%
Evidence Level	L2
Singapore Market Status	Not marketed
Number of Registrations	0
Recommended Decision	Proceed with Guardrails

Note: This is a multi-indication evaluation pack (10 predictions total). Ranks 1–7 and 9–10 all carry L4–L5 evidence with "Hold" recommendations, primarily due to KG topology bias around rare skeletal/developmental diseases (brachydactyly-syndactyly, brachyolmia, colobomatous microphthalmia, etc.) where Indomethacin has no plausible mechanistic rationale. JIA (Rank 8) is the sole indication with genuine clinical evidence and is therefore the primary focus of this report.

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available from this evidence pack. Based on well-established pharmacology, Indomethacin is one of the most potent non-selective NSAIDs, acting by inhibiting cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes. This reduces synthesis of prostaglandins — in particular prostaglandin E2 (PGE2) — the central mediators of pain, fever, and joint inflammation. Its anti-inflammatory potency is broadly regarded as superior to most other NSAIDs in its class.

The pathological core of JIA is prostaglandin-driven synovial inflammation, joint swelling, and progressive cartilage destruction. Since PGE2 directly promotes synovial hyperplasia and leukocyte recruitment in inflamed joints, COX inhibition aligns precisely with JIA's underlying pathophysiology. This is not a novel hypothesis: historically, Indomethacin was one of the standard first-line therapies for JIA (then termed "juvenile rheumatoid arthritis" or JRA) and remains particularly noted for its efficacy in controlling systemic-onset JIA fever.

In the pre-biologic era, NSAIDs including Indomethacin formed the cornerstone of JIA management. While IL-1, IL-6, and TNF inhibitors have shifted the treatment paradigm for moderate-to-severe JIA, NSAIDs including Indomethacin remain relevant for symptom control, especially in milder oligoarticular disease. The TxGNN prediction is therefore mechanistically grounded and historically validated. The primary constraint for Singapore is the absence of any HSA product registration.

Clinical Trial Evidence

Currently no related clinical trials registered for Indomethacin in Juvenile Idiopathic Arthritis on ClinicalTrials.gov or ICTRP.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
362571	1978	Double-blind RCT	South African Medical Journal	Ketoprofen vs. indomethacin in 30 children with juvenile chronic arthritis; both drugs proved safe and effective; indomethacin emerged as the preferred drug in this head-to-head comparison
28418334	2017	Review	Balkan Medical Journal	Comprehensive overview of JIA subtypes, epidemiology, clinical features, and management strategies including NSAID use as initial therapy
1379157	1992	Review	Drugs	Pharmacological management of JRA: goals of suppressing synovitis and controlling systemic inflammation; NSAIDs including indomethacin described as core first-line agents
8422565	1993	Review	British Journal of Rheumatology	NSAIDs in paediatric rheumatic diseases; indomethacin and salicylates used for systemic JCA fever, though noted as more toxic than ibuprofen and diclofenac for joint symptom control
22573189	2012	Review/Cohort	Swiss Medical Weekly	Systemic-onset JIA (Still's disease): disease characteristics unique from other JIA subtypes; discusses long-term outcomes and role of conventional therapy including NSAIDs
5632159	1967	Case Series	Arzneimittel-Forschung	Early long-term clinical experience with indomethacin specifically in juvenile rheumatoid arthritis and Still's disease; one of the earliest primary-use reports
1884567	1991	Review	Clinical Pharmacokinetics	Pharmacokinetics of drugs used in juvenile arthritis including NSAIDs; reviews indomethacin dosing characteristics relevant to pediatric populations
7417361	1980	Comparative Cohort	Arthritis and Rheumatism	Cross-national JRA comparison (USSR vs. USA); documents therapeutic diversity including indomethacin and aspirin as contemporaneous NSAID options
28086918	2017	Cohort	Pediatric Rheumatology Online Journal	Atypical monoarthritis presentations in oligoarticular JIA; documents clinical heterogeneity and management challenges in this most common JIA subtype
23312448	2013	Research Article	Cytotherapy	Mesenchymal stromal cells from children with systemic JIA suppress innate and adaptive immune responses — provides immunological context for JIA pathogenesis

Singapore Market Information

Indomethacin is currently not registered with Singapore's Health Sciences Authority (HSA). No product authorizations are on record. Any clinical use or repurposing development in Singapore would require full HSA registration, including submission of product dossiers covering safety, quality, and efficacy.

Safety Considerations

Please refer to the package insert for safety information.

All safety fields in this evidence pack are data gaps: TFDA prescribing information warnings and contraindications have not been retrieved, and the DDI query returned no results. These are classified as blocking data gaps that must be resolved before proceeding to regulatory submission.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Indomethacin's efficacy in JIA is mechanistically well-grounded (COX inhibition → reduced PGE2 → suppression of prostaglandin-driven synovitis) and historically documented, including a direct double-blind RCT in juvenile chronic arthritis (PMID 362571) and multiple clinical reviews confirming its role in the pre-biologic JIA treatment landscape. The TxGNN score of 99.84% and L2 evidence level support advancing this candidate — but the complete absence of Singapore HSA registration and unresolved safety data gaps require structured remediation before proceeding.

To proceed, the following is needed:

Regulatory pathway: Initiate HSA product registration; no Singapore marketing authorization currently exists
Safety data (Blocking): Retrieve and review full prescribing information warnings, contraindications, and special population precautions (pediatric dosing, hepatic/renal considerations)
MOA documentation: Retrieve DrugBank MOA record to complete mechanistic rationale for regulatory dossier
DDI profile: Re-query drug interaction databases (e.g., DrugBank DDI, Lexicomp) — current query returned no results, which is likely a data issue rather than absence of interactions
Comparative effectiveness: Evaluate positioning relative to current JIA biologics (anakinra, tocilizumab, etanercept); define the patient population where Indomethacin adds value (mild oligoarticular disease, systemic fever control, adjunctive use)
Pediatric PK/PD: Confirm appropriate dosing and safety monitoring parameters for the Singapore pediatric JIA population

This report is for research reference only and does not constitute medical advice. All repurposing candidates require clinical validation before therapeutic application.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.